Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: Clinical benefits and cost-effectiveness

Archives of Internal Medicine

Volumn 162, Issue 22, 2002, Pages 2545-2556

  Kuehne, Felicitas C ^a   Bethe, Ullrich ^b   Freedberg, Kenneth ^a,c   Goldie, Sue J ^a,d  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Harvard Prog Econ Eval Med Tech   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON DERIVATIVE; CD4 ANTIGEN; PEGYLATED ALPHA INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIFE EXPECTANCY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0037049367     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.22.2545     Document Type: Article

References (189)

1. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: Diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med. 2000;160:3365-3373.
2. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: Clinical issues in coinfection. Am J Med. 1999;107(suppl):79S-84S.
3. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS. 1999;13:539-546.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
5. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
6. Di Martino V, Ezenfis J, Tainturier MH, et al. Impact of HIV coinfection on the long-term outcome of HCV cirrhosis. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/567.htm. Accessed April 23, 2001. Abstract 567.
7. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: Biological, clinical, and therapeutic implications. J Hepatol. 1999;31:119-123.
8. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(suppl 1):21S-28S.
9. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35.
10. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
11. Valdez H, Chowdhry TK, Asaad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: Analysis of 260 deaths during 1995-1999. Clin Infect Dis. 2001;32:1487-1493.
12. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:1793-1795.
13. Bonnet F, Morlat P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy: Aquitane Cohort France, 1998-1999. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/299.htm. Accessed April 23, 2001. Abstract 299.
14. Di Perri G, Raiteri R, Bonora S, et al. Liver failure from HCV as the current leading cause of death in HIV-infected patients in Northern Italy. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/573.htm. Accessed April 23, 2001. Abstract 573.
15. Ahmad S, Pulvirenti J, Shastri P, Irfan M, Ariga D. Death in HIV-infected inpatients in the HAART era: An evaluation of mortality in an inner-city hospital. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/300.htm. Accessed April 23, 2001. Abstract 300.
16. Justice A, Chang C, Fusco J, et al. Extrapolating long-term HIV/AIDS survival in the post-HAART era. In: Program and Abstracts of the 39th International Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 1158.
17. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr. 2000;24:211-217.
18. Martin-Carbonero L, Soriano V, Valencia M, Lopez M, Gonzalez-Lahoz J. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/297.htm. Accessed April 23, 2001). Abstract 297.
19. Klein M, Lalonde R, Suissa S. HCV coinfection is associated with increased morbidity and mortality among HIV-infected patients. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/569.htm. Accessed April 23, 2001. Abstract 569.
20. Kim WR, Gross JB Jr, Poterucha JJ, Locke GR, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology. 2001;33:201-206.
21. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol. 1994;87:555-561.
22. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS. 1995;1995:1131-1136.
23. Beld M, Penning M, Lukashov V, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology. 1998;244:504-512.
24. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis. 1996;174:690-695.
25. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus: The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993;6:602-610.
26. Graham C, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis. 2001;33:562-569.
27. Allory Y, Charlotte F, Benhamou Y, Opolon P, Le Charpentier Y, Poynard T. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study. Hum Pathol. 2000;31:69-74.
28. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol. 1998;28:945-950.
29. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis. 2001;183:1112-1115.
30. Benhamou Y, Bochet M, Di Martino V, et al, for the Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054-1058.
31. Benhamou Y, Bochet M, Di Martino V, et al. Anti-protease inhibitor therapy decreases the liver fibrosis progression rate in HIV-HCV coinfected patients [abstract]. Hepatology. 1999;30:362A.
32. Darby S, Wewart D, Giangrande P, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425-1431.
33. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol. 1997;92:1130-1134.
34. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999;179:1254-1258.
35. Puoti M, Patroni A, Zanini S, et al. Hepatitis virus coinfections, antiretrovirals hepatotoxicity, and risk of death in HIV-infected persons: Prospective cohort study. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/576.htm. Accessed April 23, 2001. Abstract 576.
36. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis. 1995;14:949-953.
37. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
38. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology. 1994;20:1152-1155.
39. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis. 1996;23:1117-1125.
40. Daar E, Lynn H, Gomperts E, et al, for the Hemophilia Growth and Development Study. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis. 2001;183:589-595.
41. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(suppl 1):S77-S84.
42. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
43. Martin J, Lopez M, Arranz R, et al. Impact of hepatitis C in HIV-infected individuals in an urban center in Madrid, Spain. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/572.htm. Accessed April 23, 2001. Abstract 572.
44. Piroth L, Grappin M, Cuzin L, et al. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat. 2000;7:302-308.
45. Rancinan C, Neau D, Saves M, et al. Does HCV coinfection modify survival in HIV-infected patients on combinations of antiretrovirals? Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/321.htm Accessed April 23, 2001. Abstract 321.
46. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trials. BMJ. 2001;323:1151-1155.
47. Poynard T, Marcellin P, Lee SS, et al, for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
48. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sönnerborg A, Weiland O. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 1998;351:83-87.
49. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
50. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: A rapid and systematic review. Health Technol Assess. 2000;4:1-67.
51. Cummings J, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomised trials. JAMA. 2001;285:193-199.
52. Schalm SW, Weiland O, Hansen BE, et al, for the Eurohep Study Group for Viral Hepatitis. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Gastroenterology. 1999;117:408-413.
53. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG, for the International Hepatitis Interventional Therapy Group. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol. 2000;95:1524-1530.
54. Wong JB, Davis GL, Pauker SG. Cost-effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med. 2000;108:366-373.
55. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-865.
56. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha-2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318-1324.
57. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866-874.
58. Wong JB. Cost-effectiveness of treatments for chronic hepatitis C. Am J Med. 1999;107(suppl):74S-78S.
59. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. Ann Intern Med. 2000;133:665-675.
60. Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol. 2001;36:870-876.
61. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol. 2000;33:651-658.
62. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2001;13:483-488.
63. Kim WR, Poterucha JJ, Gross JB Jr. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. Hepatology. 2000;31:807-808.
64. Zeuzem S, Feinman V, Rasenack J, et al. Peg-interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
65. Reddy K, Wright TL, Pockros P, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33:433-438.
66. Glue P, Fang JW, Rouzier-Panis R, et al, for the Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556-567.
67. Glue P, Rouzier-Panis R, Raffanel C, et al, for the Hepatitis C Intervention Therapy Group. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology. 2000;32:647-653.
68. Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis. 2000;20:185-199.
69. Lindsay K, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
70. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965.
71. Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut. 2001;49(suppl 1):11-121.
72. European Association for Study of the Liver. EASL International Consensus Conference on hepatitis C. J Hepatol. 1999;31(suppl 1):3-8.
73. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47(RR-19):1-39.
74. National Institute of Diabetes and Digestive and Kidney Diseases. Chronic Hepatitis C: Current Disease Management. Available at: http://www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnhepc.htm. Accessed November 16, 2001.
75. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology. 1997;26:15S-20S.
76. Sherman K, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trials Group. Clin Infect Dis. 2002;34:831-837.
77. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
78. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1999;48(RR-10):1-59.
79. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Available at: http://www.hivatis.org/guidelines/adult/Aug13_01/text/testing.html. Accessed November 25, 2001.
80. Mattson L, Sönnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers. Liver. 1993;13:274-278.
81. Kao JH, Tsai SL, Chen PJ, et al. A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: Comparison between posttransfusion and sporadic patients. J Hepatol. 1994;21:244-249.
82. Seeff LB, Buskell-Bales Z, Wright EC, et al, for the National Heart, Lung, and Blood Institute Study Group. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med. 1992;327:1906-1911.
83. Pagliaro L, Peri V, Linea C, Camma C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol. 1999;31:28-44.
84. Vaquer P, Canet R, Liompart A, Riera J, Obrador A, Gaya J. Histological evolution of chronic hepatitis C: Factors related to progression. Liver. 1994;14:265-269.
85. Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol. 1992;27:812-816.
86. Shev S, Dhillon AP, Lindh M, et al. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver. 1997;17:215-223.
87. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol. 1993;88:240-243.
88. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992;16:273-281.
89. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-1340.
90. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology. 1996;23:695-699.
91. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
92. Christensen E, Krintel JJ, Hansen SM, et al. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis: Survival and prognostic factors. Scand J Gastroenterol. 1989;24:999-1006.
93. Serfaty L, Aumaître H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435-1440.
94. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-1801.
95. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: Natural history and prognostic factors. Hepatology. 1987;7:122-128.
96. Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 1997;92:66-72.
97. SEER Cancer Statistics Review, 1973-1994. Surveillence, Epidemiology, and End Results Web site. Available at: http://www-seer.ims.nci.nih.gov/. Accessed July 7, 2001.
98. Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: A study of 134 outpatients. Am J Gastroenterol. 1993;88:514-519.
99. National Center for Health Statistics. Vital Statistics of the United States, 1992. Washington, DC: Public Health Service; 1996.
100. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA. 1996;275:1329-1334.
101. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.
102. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
103. Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: Using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002;162:921-928.
104. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release P04. Springfield, Va: National Technical Information Service; 1995.
105. Longini IJ, Clark WS, Byers RH, et al. Statistical analysis of the stages of HIV infection using a Markov model. Stat Med. 1989;8:831-843.
106. Patil R, Cotler SJ, Banaad-Omiotek G, et al. Physicians' preference values for hepatitis C health states and antiviral therapy: A survey. BMC Gastroenterol. 2001;1:6.
107. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22;27-38.
108. Bozzette SA, Berry SH, Duan N, et al, for the HIV Cost and Services Utilization Study Consortium. The care of HIV-infected adults in the United States. N Engl J Med. 1998;339:1897-1904.
109. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care. 1996;34:702-722.
110. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115-1128.
111. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209-212.
112. Foster GR. Hepatitis C virus infection: Quality of life and side effects of treatment. J Hepatol. 1999;31(suppl 1):250-254.
113. Bonkovsky HL, Woolley JM, for the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology. 1999;29:264-270.
114. Ware JE, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment. Hepatology. 1999;30:550-555.
115. Neary M, Cort S, Bayliss M, Ware JE Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis. 1999;19(suppl 1):77-85.
116. McHutchison J, Ware JE, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol. 2001;34:140-147.
117. Younossi Z, Boparai N, McCormick M, Price L, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol. 2001;96:579-583.
118. Younossi Z, Boparai N, Price L, et al. Health-related quality of life in chronic liver disease: The impact of type and severity of disease. Am J Gastroenterol. 2001;96:2199-2205.
119. Cotler S, Jensen D. Treatment of hepatitis C virus and HIV co-infections. Clin Liver Dis. 2001;5:1045-1061.
120. Fontana RJ, Moyer CA, Sonnad S, et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol. 2001;96:170-178.
121. Rasenack J, Zeuzem S, Feinman S, et al. Therapy with Pegylated Interferon Alfa-2a Significantly Enhances Quality of Life Compared with Standard Interferon [abstract]. Paper presented at: The American Association for the Study of Liver Diseases; October 27-31, 2000; Dallas, Tex.
122. Treadwell JR, Kearney D, Davila M. Health profile preferences of hepatitis C patients. Dig Dis Sci. 2000;45:345-350.
123. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30:1299-1301.
124. Hussain K, Fontana RJ MC, Su GL, Sneed-Pee N, Lok AS. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:2732-2744.
125. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs. JAMA. 1998;280:2088-2093.
126. Chong C. Health state utilities and quality of life in hepatitis C patients. Paper presented at: 23rd Annual Meeting of the Society for Medical Decision Making; October 21-24, 2001; San Diego, Calif.
127. Siebert U. Health related quality of life in chronic hepatitis C patients: A comparison of different utility assessment methods. Paper presented at: 23rd Annual Meeting of the Society for Medical Decision Making; October 21-24, 2001; San Diego, Calif.
128. 2000 Drug Topics: Red Book. Montvale, NJ: Medical Economics; 2000.
129. Bureau of Labor Statistics. Statistical Abstract of the United States: Consumer Price Index - All Urban Consumers. Washington, DC: Bureau of the Census; 2000.
130. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569.
131. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001;161:2231-2237.
132. AIDS treatment data network. Hepatitis C Action and Advocacy Coalition Web site. Available at: http://www.atdn.org. Accessed December 28, 2001.
133. Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust. 1994;160:268-272.
134. 2000 Clinical Diagnostic Laboratory Fee Schedule Public Use File. Baltimore, Md: Health Care Financing Administration; 2000.
135. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
136. AIDS Cost and Services Utilization Survey: Public Use Tapes 4 and 5. Springfield, Va: National Technical Information Service; 1994. No. PB94189891.
137. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54-62.
138. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med. 1999;130:97-107.
139. Tradati F, Colombo M, Mannucci PM, et al, for the Study Group of the Association of Italian Hemophilia Centers. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. Blood. 1998;91:1173-1177.
140. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis. 1992;165:723-726.
141. Causse X, Payen JL, Izopet J, Babany G, Girardin MF, for the French Multicenter Study Group. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. J Hepatol. 2000;32:1003-1010.
142. Garcia-Samaniego J, Soriano V, Bravo B, et al. Efficacy and safety of alpha interferon therapy for chronic hepatitis C in HIV patients [abstract]. Hepatology. 1994;20:162A.
143. Hanley JP, Jarvis LM, Andrew J, et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs: Influence of virus load, genotype, and liver pathology on response. Blood. 1996;87:1704-1709.
144. Landau A, Batisse D, Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS. 2000;14:839-844.
145. Mauss S, Heintges T, Adams O, et al. Treatment of chronic hepatitis C with interferon-alpha in patients infected with the human immunodeficiency virus. Hepatogastroenterology. 1995;42:528-534.
146. Perez-Olmeda M, Gonzalez J, Garcia-Samaniego J, et al. Interferon + ribavirin in HIV+ patients with chronic hepatitis C. Paper presented at: 7th Conference on Retroviruses and Opportunistic Infections; January 30-Feberuary 2, 2000; San Francisco, Calif. Available at: http://www.retroconference.org/2000/abstracts/abstracts/abstracts/284.htm. Accessed April 23, 2001. Abstract 284.
147. Soriano V, Nedjar S, Garcia-Samaniego J, et al, for the Hepatitis HIV Spanish Study Group. High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. J Hepatol. 1995;22:598-599.
148. Zylberberg H, Benhamou Y, Lagneaux J, et al. Safety and efficacy of interferonribavirin combination therapy in HCV-HIV coinfected subjects: An early report. Gut. 2000;47:694-697.
149. Yano M. Advances in hepatitis C: Sero-epidemiology and natural history. J Gastroenterol Hepatol. 1992;7:549-550.
150. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-675.
151. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-1695.
152. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.
153. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs intravenous drug use. Hepatology. 1993;18:1338-1343.
154. Hopf U, Moller B, Kuther D, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990;10:69-76.
155. Koretz RL, Brezina M, Polito AJ, et al. Non-A, non-B posttransfusion hepatitis: Comparing C and non-C hepatitis. Hepatology. 1993;17:361-365.
156. Seeff LB. The natural history of hepatitis C-A quandary. Hepatology. 1998;28:1710-1712.
157. Kenny-Walsh E, and the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228-1233.
158. Muller R. The natural history of hepatitis C: Clinical experiences. J Hepatol. 1996;24:52-54.
159. Seeff LB, Miller RN, Rabkin CS, et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105-111.
160. Sabin C, Telfer P, Phillips A, Bhagani S, Lee C. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis. 1997;175:164-168.
161. Romeo R, Rumi MG, Donato F, et al. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hepat. 2000;7:297-301.
162. Makris M, Preston F, Rosendaal F, Underwood J, Rice K, Triger D. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol. 1996;94:746-752.
163. Pol S, Zylberberg H. Interactions between the human immunodeficiency virus and hepatitis C virus. Rev Med Intern. 1998;19:885-891.
164. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival. Clin Infect Dis. 1999;29:150-154.
165. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for HPV-induced anal squamous intraepithelial lesions in homosexual men. Am J Med. 2000;108:634-641.
166. Staszewski S, Morales-Ramirez J, Tashima KT, et al, for the Study 006 Team. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
167. Hammer SM, Squires KE, Hughes MD, et al, for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
168. Baxter JD, Mayers DL, Wentworth DN, et al, for the CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83-F93.
169. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
170. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up. JAMA. 1998;280:35-41.
171. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial: Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-937.
172. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
173. Sulkowski M, Mahta S, Thomas D, et al. Hepatotoxicity associated with NNRTI use: Role of drugs and chronic viral hepatitis. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/618.htm. Accessed April 23, 2001. Abstract 618.
174. Monforte A, Ade A, Bugarini R, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr. 2001;28:114-123
175. den Brinker M, Wit FW, Wertheim-van PM, et al. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
176. Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, Anton P, Gonzalez-Lahoz J. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS. 1998;12:1112-1113.
177. Melvin D, Lee J, Belsey E, Arnold J, Murphy R. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS. 2000;14:463-465.
178. Servoss J, Sherman KE, Robbins G, et al. Hepatotoxicity in the US Adult AIDS Clinical Trial Group [abstract]. Gastroenterology. 2001;120:283.
179. Roychowdhury A. The impact of HIV therapy with HAART on HCV disease in HIV/HCV co-infection. Paper presented at: Digestive Disease Week 2001 Conference; May 20-23, 2001; Atlanta, Ga. Abstract 1894.
180. Bochet M, DeTorres M, Valantin V, et al. Efficacy and tolerance of IFN and ribavirin for chronic hepatitis C in HIV-infected patients. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/574.htm. Accessed April 23, 2001. Abstract 574.
181. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
182. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(suppl 2):S96-S116.
183. Filippini P, Coppola N, Scolastico C, et al. Can HCV affect the efficacy of antiHIV treatment? Arch Virol. 2000;145:937-944.
184. Torre D, Tambini R CF, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2001;33:1579-1585.
185. Esnaola N. Comparison of addictive and multiplicative utility functions to predict the utilities of combined health states. Paper presented at: 23rd Annual Meeting of the Society for Medical Decision Making; October 21-24, 2001; San Diego, Calif.
186. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90:1100-1111.
187. Torrance GW. Social preferences for health states: An empirical evaluation of three measurement techniques. Socioecon Planning Sci. 1976;10:128-136.
188. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci. 1997;42:2482-2486.
189. Davis GL, Balart LA, Schiff ER, et al. Assessing health related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther. 1994;16:334-343.